Vyriad

Oncolytic virus therapies

This clinical-stage biotechnology company develops engineered oncolytic virus therapies for cancer patients to destroy tumours and stimulate the immune system.

Vironexis

The company develops adeno-associated virus gene therapies to treat blood-based cancers and prevent solid tumour metastasis for patients with oncological and immune disorders.

Gene Therapy Delivery Methods

This company develops viral and non-viral vector platforms to provide genetic material delivery solutions for biotechnology firms and healthcare providers.

Stridebio

This company develops engineered viral vectors and gene therapies for patients with rare genetic diseases.

IconOVir

The company develops engineered oncolytic virus therapies to treat patients with solid tumours.

KaliVir Immunotherapeutics

This company develops oncolytic viral immunotherapies for cancer patients using a proprietary platform to engineer viruses that target and kill solid tumours.

Spot Biosystems

This company develops non-viral gene therapy delivery platforms using extracellular vesicles to treat genetic diseases for pharmaceutical partners and healthcare providers.

Salve Therapeutics

The company develops a bioengineering platform for designing and testing viral gene therapies to treat genetic disorders for biotechnology and pharmaceutical organisations.